Celcuity (NASDAQ:CELC) Issues Earnings Results

Celcuity (NASDAQ:CELC) announced its quarterly earnings results on Thursday. The company reported ($1.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.30, FiscalAI reports.

Here are the key takeaways from Celcuity’s conference call:

• Commercial launch of REVTORPYK is off to a strong early start: within about a month of availability, 78% of Celcuity’s 36 priority accounts had ordered the drug, and 91% of U.S. commercial and Medicare lives were covered. The company also reported a preferred NCCN recommendation and inclusion in three of four major provider pathways.
• VIKTORIA-1 results presented at ESMO showed encouraging efficacy across patient subgroups, including median progression-free survival of 21.5 months for the triplet in patients without liver metastases, and higher response rates than the comparator. Celcuity also highlighted lower treatment-discontinuation rates with gedatolisib regimens, while noting the results are from clinical trials.
• Potential growth extends beyond the current second-line indication: Celcuity expects to submit data for the PIK3CA-mutant cohort to global regulators, is conducting first-line breast cancer trials, and plans a randomized phase II prostate cancer study in the first half of 2027. These programs remain subject to clinical and regulatory outcomes.
• Third-quarter net loss widened to $73.3 million from $43.8 million a year earlier as operating expenses rose, largely reflecting commercial launch investment. Celcuity ended the quarter with $642.7 million in cash, equivalents and short-term investments and said it expects funding through 2029; it reported no product revenue in the quarter.

Celcuity Stock Performance

Shares of CELC stock traded down $5.20 during midday trading on Thursday, hitting $64.04. 1,423,630 shares of the company were exchanged, compared to its average volume of 1,686,345. Celcuity has a 52 week low of $53.54 and a 52 week high of $151.02. The firm has a market capitalization of $3.13 billion, a P/E ratio of -14.89 and a beta of 0.16. The firm’s 50 day moving average price is $75.64 and its two-hundred day moving average price is $99.57. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CELC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Tuesday, September 1st. TD Cowen reaffirmed a “buy” rating and set a $145.00 price target on shares of Celcuity in a research report on Wednesday, October 21st. Zacks Research downgraded shares of Celcuity from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Stifel Nicolaus cut their price target on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, Needham & Company LLC decreased their price target on Celcuity from $140.00 to $134.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $152.57.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.